Products
| Catalog No | Chemical Name | CAS Number | Purity | Chemical Structure |
|---|---|---|---|---|
| 20576 | STX-721 | 2765525-82-2 | ≧98.0% |  |
| STX-721 is a next-generation, orally delivered therapy, designed with potential best- | ||||
| 20577 | LY-3522348 | 2568608-48-8 | ≧98.0% |  |
| LY-3522348 is a ketohexokinase (KHK) inhibitor. | ||||
| 20594 | JTE-151 | 1404380-58-0 | ≧98.0% |  |
| JTE-151 is a novel RORγ inverse agonist. | ||||
| 20608 | Ninerafaxstat | 2254741-41-6 | ≧98.0% |  |
| Ninerafaxstat is a biochemical that decreases fatty acid oxidation and improves mitoc | ||||
| 20618 | Pirtobrutinib | 2101700-15-4 | 98% Min. |  |
| 20639 | SOP1812 (QN-302) | 2546091-70-5 | ≧98.0% | _2546091-70-5.png) |
| QN-302 is a G-quadruplex (G4)-selective transcription inhibitor. | ||||
| 20640 | FLAG-003 | 1614235-14-1 | ≧98.0% |  |
| FLAG-003 is a multi-acting, water-soluable small molecule therapeutic designed to tar | ||||
| 20641 | KP-302 ( Synonyms: Lucid-21-302 ; Lucid-MS ) | 2082765-42-0 | ≧98.0% | _2082765-42-0.png) |
| KP-302 ( Synonyms: Lucid-21-302 ; Lucid-MS ) is a small molecule inhibitor of protein | ||||
| 20642 | OATD-02 | 2146132-73-0 | ≧98.0% |  |
| OATD-02, an orally available dual arginase inhibitor (ARG1 and ARG2), is in phase I c | ||||
| 20650 | Sonrotoclax (BGB-11417) | 2383086-06-2 | ≧98.0% |  |
| Sonrotoclax is an antineoplastic. | ||||
| 262401 | MRTX1719 | 2630904-45-7 | ≧96.0% | |
| MRTX1719 is a potent and selective binder to the PRMT5•MTA complex and selectively | ||||
| 24002 | Tert-butyl 6,11-dioxo-6,11-dihydro-5H-benzo[b]carbazole-2-carboxylate | 3024657-88-0 | ≧96.0% |  |
| Tert-butyl 6,11-dioxo-6,11-dihydro-5H-benzo[b]carbazole-2-carboxylate, CAS 3024657-88 | ||||